Tracheostomy ventilation in motor neurone disease: a snapshot of UK practice
Related Articles
Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial
Background Coformulated sodium phenylbutyrate/taurursodiol (PB/TURSO) was shown to prolong survival and slow functional decline in amyotrophic lateral sclerosis (ALS). Objective Determine whether PB/TURSO prolonged tracheostomy/ventilation-free…
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
Background and Objectives People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive disease-modifying therapies (DMTs).…
Diagnosing ALS: the Gold Coast criteria and the role of EMG
In September 2019, a group of international neurologists gathered in Gold Coast, Australia, to deconstruct the diagnostic process for amyotrophic lateral sclerosis (ALS) and to…
Respiratory support in a population-based ALS cohort: demographic, timing and survival determinants
Introduction Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease leading to a progressive loss of motor function and cognitive impairment of the frontotemporal type (FTD).…
CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies
Background and Objective Severe attacks of myelin oligodendrocyte glycoprotein (MOG) antibody–associated disorder (MOGAD) and aquaporin-4 (AQP4) antibody–positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) may require ventilatory…
English
العربية
简体中文
Nederlands
Français
Deutsch
Italiano
Português
Русский
Español
Responses